BPC-157 (Body Protection Compound 157) occupies an unusual position in the peptide research landscape: it is supported by a relatively coherent preclinical literature spanning more than two decades, yet remains essentially untouched by Western clinical trials. This review summarizes the mechanistic findings that have driven sustained interest in the molecule despite the absence of formal regulatory development.
The principal in vivo phenotype across BPC-157 studies is accelerated repair of injuries that depend critically on early vascular invasion: tendon-to-bone insertions, transected ligaments, segmental muscle lesions, and gastric mucosal damage. The proposed central mechanism involves up-regulation of vascular endothelial growth factor receptor 2 (VEGFR2) and downstream activation of endothelial nitric oxide synthase (eNOS), driving early angiogenic sprouting in the wound microenvironment. A complementary effect on the growth-hormone receptor (GHR) in fibroblasts and tenocytes amplifies collagen synthesis in healing connective tissue.
Secondary mechanisms include modulation of the gut-brain axis (BPC-157 administration alters dopaminergic and serotonergic transmission in stress models), anti-inflammatory effects on neutrophil recruitment, and a reproducible counter-regulatory effect against NSAID-induced gastric damage. The peptide’s exceptional stability — it tolerates oral administration, gastric pH, and prolonged storage — distinguishes it from most peptides of comparable size.
The gap between this preclinical record and the absence of registered clinical trials reflects a patent and commercial landscape rather than a methodological objection. BPC-157 remains, for now, a research compound: one of the most extensively characterized but least clinically translated peptides in the field.